General Summing Up
Dr R Norrby (University ofGothenburg Sweden)
The introduction of a new antibiotic raises several questions which one would like to have answered. In an attempt to summarize this meeting I will go through some of them.
The first question is: From a clinical point of view does cefuroxime have theoretical characteristics that make it likely to become more than a minor innovation ? This is one of the easy questions. The answer is undoubtedly yes. The wide antibacterial spectrum covering important Gram negative and Gram positive pathogens including some which can be characterized as difficult-totreat organisms such as /-lactamase producing strains of Ha?mophilus influenza, and Neisseria gonorrha?w as well as Enterobacter gives cefuroxime advantages over other antibiotics. This antibacterial spectrum, in combination with high resistance to degradation by P-lactamases from both Gram negative and Gram positive organisms make cefuroxime a rather unique antibiotic from a theoretical point of view.
However good the activity of an antibiotic in vitro, that certainly does not guarantee that it is effective in vivo. So, the second question is: Is cefuroxime active in experimental infections? With many new antibiotics this rather elementary question cannot be answered. The reason is that many of the experimental models used for in vivo studies of antibiotic activity are extremely artificial and permit no extrapolation to the situation in an infection in man. I do not, for example, think that any of you have seen a patient in whom bacteria have been introduced directly into the peritoneal cavity shortly before intraperitoneal administration of antibiotics. But the models for experimental infections used at the laboratories of Glaxo Research Ltd are highly relevant and experimental pyelonephritis and subcutaneous infections allow closer analogy to the usefulness of antibiotics in man. Thus, with cefuroxime the in vivo studies clearly proved that it could cure bacterial infections in animals and the physicians running the very first clinical trial were able to start their treatment of infected patients with sound theoretical documentation on the drug.
The third question is important but maybe not possible to answer to the extent one would like: What are the pharmacokinetic characteristics of cefuroxime ? The data presented here give evidence that high serum concentrations of cefuroxime are achieved even after moderate doses and that it is excreted in the urine in an active form, giving a recovery of at least 80% of the dose within 6 h of administration. Moreover, we know that cefuroxime has a serum half-life which is longer than for other cephalosporins with the exceptions of cefazolin and cephaloridine. The pharmacokinetic data obtained in patients have been well correlated with volunteer data.
We know that cefuroxime can penetrate into bone and that it seems to give fairly high CSF concentrations when given to patients with bacterial meningitis. But we do not know very much about its ability to penetrate into peripheral tissues and we do not know anything about the extent of its penetration into infected peripheral tissues although from the clinical results obtained it is obvious that some cefuroxime does reach such tissues.
Animal tissue studies have demonstrated that cefuroxime has a penetration into tissue fluid which is equal to that of cephaloridine and clearly superior to that of cefoxitin. But we still lack important information about the pharmacokinetics of cefuroxime, just as we lack that information on antibiotics that have been on the market for several years. 1 would like to take this opportunity to advocate that in the future, Glaxo supports important projects on the pharmacokinetics of antibiotics.
The fourth question is of course the most important one: Does cefuroxime work in the infected human being? The reports presented at this Symposium cover a large number of patients with various types of infection. The high rates of clinical and bacteriological cures allow the conclusion that cefuroxime is clinically effective in respiratory tract infections, soft tissue infections, osteitis, genito-urinary tract infections (including gonorrhoea) and in biliary tract infections.
In a very small number of patients cefuroxime has also been used for the treatment of bacterial meningitis. Although the number of patients treated so far is very small I would like to go into some detail on this latter indication. The first reason for that is that the in vitro spectrum of cefuroxime is optimal when one considers the most common bacteria causing meningitis. Moreover, it seems to be able to pass through inflamed meninges, even if it is not likely to give high CSF concentration in patients with normal blood-CSF barriers. I know that I am discussing a very controversial subject, since the cephalosporins have so far proved to be relatively ineffective in purulent meningitis. Cases of pneumococcal meningitis developing during cephalothin treatment are well known. Cephaloridine has been reported to give good clinical results in meningococcal meningitis but is definitely fails in pneumococcal meningitis if administered systemically.
When discussing these questions I would like to remind you of the results recently obtained by Sande's group in Charlottesville, Virginia. In experimental meningitis in rabbits they have been able to demonstrate that cephalosporins give no or very poor bacterial elimination in CSF until the CSF concentrations exceed 5 times the MICs of the pathogens tested. The (so far very limited) data obtained with cefuroxime indicate that in man, concentration far above 5 times the MICs of these pathogens might easily be achived in cases of purulent meningitis. I think CNS infections should be one of the major research areas for cefuroxime in the near future. To summarize the question whether cefuroxime is clinically effective or not the answer is, yes, I do believe that it is.
The fifth question is also important: Is it safe? The reports we have listened to clearly demonstrate that a low frequency of adverse reactions can be expected with cefuroxime. So far it has not been found to be nephrotoxic, either in animals or in man. ft should, however, be noted that clinical trials with carefully monitored dosages and careful follow-up of renal functions are a little artificial in comparison to the real clinical situation. Before 1 make a statement that cefuroxime is definitely not nephrotoxic I would like to see what happens when it comes into the hands of a clumsy colleague who gives it in excessive doses to patients with severely impaired renal function, maybe even in combination with other potentially nephrotoxic drugs. If these patients do not react with cefuroxime-associated tubular damage, then it is not nephrotoxic. At this moment, however, it can be stated that cefuroxime is not nephrotoxic in man when properly used.
Other side-effects have been found very rarely. We found a high incidence of transaminase increases in our patients but they were in most cases the result of alcoholism or other pre-existing liver diseases. In no case did treatment have to be stopped because of increased liver transaminases. Cefuroxime has been found to be well tolerated after both i.v. and i.m. administration and it is almost as little of a local irritant as cephaloridine.
The sixth question is: How should it be used, and which are the optimal regimens for cefuroxime treatment? From the results presented here and from our own experience with cefuroxime, I would like to propose the following treatment schedules.
My dosage recommendations, after some discussion with Glaxo, have to be a bit sweeping. fn adults with normal or moderately decreased renal function down to a clearance of about 30 m/min, f think that in mild or moderately severe infections the best documented dose is 750 mg three times daily, i.m. or i.v. All doses are given as doses per 1.73 m2 and should, of course, be adjusted for the very heavy or the very light individual. In severe infections, f think in most cases 1500 mg three times daily (i.v. for practical reasons) should be enough. I think it is safe to go up to 6 g or, as Dr Gentry suggested, even to 12 g per day when required.
In severe renal failure, we must, of course, reduce doses. It is clear that the loading dose should be the same as that given to patients with normal renal function. However, I still want to see monitoring by serum concentration assays of the subsequent doses since failure to do so can lead to two mistakes. Either it can allow the use of too high doses with subsequent risk of accumulation and toxicity. Or (which I think could be even more serious) it could lead to the use of too low doses with the risk of sub-therapeutic concentrations, clinical failure and perhaps even the development of resistance. Therefore, until we know much more about the use of cefuroxime in renal failure, let us do serum concentration assays, as we do with the aminoglycosides.
With regard to patients on hemodialysis, I think it has become clear that the full loading dose and then 50 % of the loading dose at the end of the dialysis is desirable. I think it is vital to give the loading dose rather close to the dialysis.
What dosages should be used in pediatric patients? In infants, I suggest 30-100 mg/kg body weight per day in three doses. For the immature and neonates, a lower dose, probably around 30 mg/kg body weight per day, divided into two doses seems to be preferred. For older children adult dosages can be used, provided corrections are made for the weight of patients.
Compared with the other cephalosporins, are there clinical advantages that motivate a change from an established cephalosporin to cefuroxime; moreover, how does cefuroxime compare with other new cephalosporins? Table I shows the parenteral cephalosporins on the market, or close to the market.
The dotted line indicates the border between what has been called the first and second generations of cephalosporins. ft is my opinion that if use of cefuroxime on very wide indications which will probably result in a short life time, or a restricted use in patients really in need of the drug. Then, I am sure, it will be an important drug for many years. It is quite obvious which I prefer.
In severe indications of unknown retiology, cefuroxime could fit in very well. One has to consider the whole spectrum, including Pseudomonas and some indole-positive Proteus strains. I think one has to be careful in patients hospitalized for a long period. As to lower respiratory tract infections in compromised patients, I fully agree with Dr Sterner that it should not be used in the ordinary pneumococcal pneumonias, and it should not be used in patients with cases of aspiration pneumonia, as there we often have a Bacteroidesfragilis problem. Regarding soft tissue infections, there is often a mixed Gram positive/ Gram negative flora. Finally, we include biliary tract infections and gonorrhoea.
In HamophVlus influenza, infections, 1 think that high stability to the ,3-lactamase is very important. As a substitute for penicillins in cases of penicillin hyper-sensitive patients, I would not give cefuroxime to patients with anaphylaxis, but might to other sensitive individuals. 1 listened to the papers on neonatal septictmia. I believe that this can be a good drug, but we still lack information. I would prefer it to the combination of ampicillin and gentamicin, as gentamicin does not go into CSF. Finally, there are two less certain indications: bacterial meningitis which should, f think, be further studied; prophylaxis where it is to be used very restrictively, probably in abdominal surgery and also possibly in thoracic surgery. Otherwise, there should be the maximum of restrictions.
As I am obviously the last non-Glaxo speaker of this Symposium, I want to take this opportunity to thank Glaxo for arranging a meeting which has given me, and I imagine also others, many new aspects of cefuroxime to consider. The quality of the papers given has been high and the discussions in many sessions have been highly relevant. fn my view, Glaxo has done a tremendous job in bringing cefuroxime to us and arranging this Symposium. I congratulate Glaxo on an excellent Symposium and a very good new antibiotic which is certainly one of the major innovations in this field within the last 2-3 years. cefuroxime provides what it promises, then we can forget about the first generation of cephalosporins. Personally, 1 can see no reason why cefuroxime should not replace drugs like cefazolin, cephalexin and cephaloridine. The indications are the same, even if the cephalosporins today are misused to a considerable extent and some new indications will be found for drugs like cefuroxime.
That leaves us with cefamandole, cefoxitin and cefuroxime. Cefamandole, I have found hard to evaluate from a clinical point of view. There are clinical failures which indicate that there may be discrepancies between in vitro and in vivo activity, which is very dangerous. Moreover, cefamandole is less ,B-lactamase resistant. In the choice between cefamandole and cefuroxime, I would undoubtedly choose the latter.
Cefoxitin and cefuroxime are both good antibiotics with approximately the same high stability to ,B-lactamase degradation. Cefoxitin seems to be somewhat inferior to cefuroxime with regard to pharmacokinetic and pharmacodynamic properties. However, it has some advantages over cefuroxime in being active against Bacteroides fragilis and Serratia and more active than cefuroxime against indole-positive Proteus. On the other hand, cefuroxime is more active than cefoxitin against some Enterobacter strains and against Gram positive pathogens.
But I think any competition between cefuroxime and cefoxitin can be avoided. Both drugs are needed and I see cefoxitin as a possible replacement for aminoglycosides in some types of infection, especially if one does not have a Pseudomonas problem. 1 finish this summary with a last question: Which are the indications for cejuroxime? First, 1 think it is important to notice that cefuroxime is a broad spectrum antibiotic which, if it is to have a long life on the market, must be used only when drugs such as benzyl penicillin, and the penilinase-resistant penicillins, cannot be used. I think that cefuroxime is a typical hospital drug with, additionally, its use in gonorrhaea. In my view it is naive to believe that cefuroxime-resistant pathogens will not emerge. I remember Dr Reeves from Bristol saying that Gram negatives will always find a way to become resistant to an antibiotic, and I think that is very true. My opinion is that we have a choice between extensive
